Disability Probationary Period

In insurance, a probationary period is a waiting period during which no benefits will be paid for a disability claim. During this period, the insurance company will review the policyholder's medical history and other relevant information to determine if the disability is related to a pre-existing condition.

Key features of a Disability Probationary Period may include:

  • The length of the waiting period is determined by the insurance company and varies by policy.
  • The probationary period typically starts on the policy's effective date or the date the policyholder becomes eligible for coverage.
  • No benefits will be paid for any disabilities that occur during the probationary period, unless they are due to an accident.
  • After the probationary period ends, benefits will be paid according to the policy's terms and conditions.
  • The purpose of the probationary period is to prevent people from purchasing a policy after they have already become disabled.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.